Study to Learn About How the Study Medicines Called PF-07976016 and PF-06882961 Are Taken Up by the Body, and if Either of Them Change How the Body Processes the Other Medicine in Otherwise Healthy Adults With Overweight or Obesity
← catalyst calendarSponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 1
Status
Terminated
Study type
Interventional
Design
Na · None · Basic science
Enrollment
21actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
The sponsor has made the decision to discontinue development of danuglipron (PF-06882961). As such, this study was discontinued prior to PF-06882961 administration.
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-03-13 | actual | When the study began enrolling |
| Primary completion | 2025-05-01 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-05-20 | actual | The whole study's end, after follow-up |
| First posted | 2025-04-04 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-08-07 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Overweight
- Obesity
Interventions
- Drug: PF-07976016
- Drug: PF-06882961
Primary outcomes
what the primary-completion date above is the date OFSteady state area under the concentration-time profile for PF-07976016
measured From 0 Hours to 24 Hours following steady-state dose
Steady state maximum observed concentration (Cmax) for PF-07976016
measured From 0 Hours to 24 Hours following steady-state dose
Steady state area under the concentration-time profile danuglipron
measured From 0 Hours to 24 Hours following steady-state dose
Steady state maximum observed concentration (Cmax) for danuglipron
measured From 0 Hours to 24 Hours following steady-state dose
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed